SCHEMBL2203344

SCHEMBL2203344

Cc1cc(OCc2ccccc2)cc(C)c1CBr

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAOB P27338 7/20 0.49
MEN1 O00255 2/20 0.47
KMT2A Q03164 2/20 0.47
ALOX5 P09917 1/20 0.47
LMNA P02545 1/20 0.46
CYP1A2 P05177 1/20 0.46
PTGS1 P23219 1/20 0.46
SLC6A2 P23975 1/20 0.46
CYP2C19 P33261 1/20 0.46
PTGS2 P35354 1/20 0.46
SLC6A3 Q01959 1/20 0.46
HIF1A Q16665 1/20 0.46
HDAC6 Q9UBN7 1/20 0.46
BCHE P06276 1/20 0.45
L3MBTL1 Q9Y468 4/20 0.45
NSD2 O96028 1/20 0.45
ABL1 P00519 1/20 0.45
PPARG P37231 1/20 0.45
RIN1 Q13671 1/20 0.45
NCOR2 Q9Y618 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27746115 0.87 MAOB (0.46) MAOBMEN1KMT2AALOX5LMNA
SCHEMBL20781419 0.83 MAOB (0.54) MAOBMEN1KMT2AALOX5LMNA
SCHEMBL2209201 0.83 MEN1 (0.51) MAOBMEN1KMT2AALOX5LMNA
SCHEMBL3629799 0.82 MAOB (0.56) MAOBMEN1KMT2AALOX5LMNA
SCHEMBL9780596 0.82 MEN1 (0.55) MAOBMEN1KMT2AALOX5MRGPRX4
SCHEMBL10903897 0.82 L3MBTL1 (0.55) MAOBMEN1KMT2AALOX5LMNA
SCHEMBL15287235 0.81 MAOB (0.54) MAOBMEN1KMT2AALOX5LMNA
SCHEMBL1143540 0.80 MAOB (0.53) MAOBMEN1KMT2AALOX5LMNA
SCHEMBL10477402 0.80 APP (0.53) MAOBMEN1KMT2AALOX5LMNA
SCHEMBL696249 0.80 S1PR1 (0.54) MAOBMEN1KMT2AALOX5LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2029579-B1 CYCLOHEXYLPYRAZOLE-LACTAM DERIVATIVES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 LILLY CO ELI (US) 2014-12-31 EP disclosed
US-7981918-B2 Cyclohexylpyrazole-lactam derivatives as inhibitors of 11-beta-hydroxysteroid dehydrogenase 1 ELI LILLY AND COMPANY (US) 2011-07-19 US disclosed
US-20090111800-A1 CYCLOHEXYLPYRAZOLE-LACTAM DERIVATIVES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 ELI LILLY AND COMPANY 2009-04-30 US disclosed
EP-2029579-A2 CYCLOHEXYLPYRAZOLE-LACTAM DERIVATIVES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 ELI LILLY AND COMPANY (US) 2009-03-04 EP disclosed
WO-2007124254-A2 CYCLOHEXYLPYRAZOLE-LACTAM DERIVATIVES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 ELI LILLY AND COMPANY (US) 2007-11-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090111800-A1 CYCLOHEXYLPYRAZOLE-LACTAM DERIVATIVES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 HSD11B1, HSD3B1, HSD17B1 MAOB 2301/4885MEN1 2040/4885KMT2A 2646/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.